leisure time -WSS

leisure time

author：hotspot 2025-08-19 18:05:19 - browse：29

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

For more on what we cover, here’s STAT’s investigation into the Mount Sinai brain-tissue research project; here’s exclusive reporting on the MorphoSys drug at the center of the Novartis acquisition, and Adam Feuerstein’s take on where it might run off the rails; and here’s STAT’s reporting on Novo Nordisk and its weight loss drug Wegovy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： What the Wegovy shortage looks like for doctors — and for patients

WSS

Medicare to cover more brain scans related to Alzheimer’s drugs

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Takeaways from AdvaMed, the largest medical devices conference

Humana CEO Bruce Broussard to step down in 2024

Better Therapeutics data on benefit with GLP

Why Charlie Gard's case is so disturbing to Americans

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

A revolution in caring for preterm infants

Psychedelics group wrestles with new pharma identity

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Wildfire smoke exposes gaps in outdoor worker protections

Nick Jonas talks about managing diabetes along with his career

At least 13 dead in Texas as scorching temps continue

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Medical leaders decry Supreme Court decision on affirmative action

Better Therapeutics data on benefit with GLP

focus

Medicare to cover more brain scans related to Alzheimer’s drugs

Life sciences deals on track to hit lowest point since 2017

What the Wegovy shortage looks like for doctors — and for patients

How should state employee insurance handle Wegovy?

VC firm General Catalyst wants to buy a health system

How doctors and nurses shape Google's AI

focus

leisure time

Wikipedia

focus